Novel TKI Plus Chemo Dramatically Shrank Advanced Head & amp; Neck Tumors

AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.

Source: CancerNetwork - April 25, 2018 Category: Cancer & Oncology Authors: Anne Landry Tags: Head & Neck Cancer Head and Neck Cancer Targets News Source Type: news